Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.

Neuropathy Score Reporting and Data System (NS-RADS) Subclass M1 (Edemalike Signal): Axial T1-weighted (A) and STIR (B) images depict denervation edemalike signal of extensor muscles of dorsal and mobile wad compartments with no fatty infiltration or atrophy consistent with NS-RADS M1.


March 4, 2022 — According to an article in ARRS’ American Journal of Roentgenology (AJR), a new reporting and data system for standardized evaluation and recording of peripheral nerve pathologies—Neuropathy Score Reporting and Data System (NS-RADS)—has been created and validated in a multicenter study.

“The proposed NS-RADS classification is accurate and reliable across different reader experience levels and a spectrum of peripheral neuropathy conditions,” wrote lead researcher Avneesh Chhabra of UT Southwestern in Dallas, TX. “NS-RADS can be used as a standardized guideline for reporting peripheral neuropathies and improved multidisciplinary communications.”

Chhabra and team’s retrospective study included 100 patients with nerve imaging examinations and known clinical diagnoses. Utilizing mutually agreed-upon qualitative benchmarks for classifying and grading peripheral neuropathies, different classes were established to account for the spectrum of underlying pathologies (unremarkable, injury, neoplasia, entrapment, diffuse neuropathy, not otherwise specified, and postintervention state) with subclasses to describe lesion severity or extent. Validation was performed by 11 fellowship-trained musculoskeletal radiologists across 10 institutions, and after initial multimedia training, all 100 cases were blind-presented to readers.

Offering a uniform lexicon and practical guideline for reporting neuropathic conditions on MRI, ultimately, NS-RADS accuracy for determining milder versus more severe categories per radiologist ranged from 88% to 97% for nerve lesions and from 86% to 94% for muscle abnormalities.

“On the basis of the overall promising interrater agreement shown in this study, we believe that the newly proposed NS-RADS classification will perform as well in routine practice as it did in this initial validation study,” the authors of this AJR article concluded

For more information: arrs.org


Related Content

News | X-Ray

Dec. 1, 2025 – Zwanger-Pesiri Radiology, one of the most respected and technologically advanced outpatient radiology ...

Time December 03, 2025
arrow
News | Interventional Radiology

Dec. 1, 2025 — GE HealthCare has unveiled the Allia Moveo,1 an image guiding solution designed to enhance mobility and ...

Time December 02, 2025
arrow
News | Archive Cloud Storage

Nov. 30, 2025 — Gradient Health, Inc. has released Atlas 2, a major upgrade to its self-service medical imaging data ...

Time December 01, 2025
arrow
News | Artificial Intelligence

Nov. 24, 2025 — Siemens Healthineers is launching artificial intelligence-enabled services to help healthcare providers ...

Time November 24, 2025
arrow
News | Artificial Intelligence

Nov. 20, 2025 — Aidoc has announced a collaboration with AdventHealth to launch one of the largest imaging AI ...

Time November 21, 2025
arrow
News | Advanced Visualization

Nov. 20, 2025 — Avatar Medical and Barco have launched Eonis Vision, marking a new evolution in how medical imaging is ...

Time November 20, 2025
arrow
News | Neuro Imaging

Nov. 19, 2025 — Royal Philips has announced an extended partnership with Cortechs.ai. Together, the companies will ...

Time November 19, 2025
arrow
News | Radiology Business

Nov. 13, 2025 — Covera Health recently announced that Advanced Radiology Services (ARS) has joined its national Quality ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Orthopedic Imaging

Nov.10, 2025 — Medical imaging technology company Adaptix Ltd. has received 510(k) clearance from the U.S. Food and Drug ...

Time November 11, 2025
arrow
Subscribe Now